Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00179582
Status:
TERMINATED
Last Update Posted:
2019-02-27
First Post:
2005-09-13
Brief Title:
Dose Ranging Study With the Probiotic Combination VSL3 in Diarrhea IBS
Sponsor:
Beth Israel Deaconess Medical Center
Organization:
Beth Israel Deaconess Medical Center
Study Overview
Official Title:
A Randomized Multi-center Double-blind Placebo Controlled Dose Ranging Study With VSL3 in Diarrhea Predominant IBS Patients
Status:
TERMINATED
Status Verified Date:
2019-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Lack of enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the effects of VSL3 on symptoms associated with diarrhea predominant IBS
Detailed Description:
The study will evaluate 2 doses of VSL3 and placebo over a 4 week period in patients presenting with diarrhea predominant IBS symptoms
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| VSL1 | None | None | None |